TY - JOUR
T1 - CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in sézary syndrome patients
AU - Wysocka, Maria
AU - Kossenkov, Andrew V.
AU - Benoit, Bernice M.
AU - Troxel, Andrea B.
AU - Singer, Elisha
AU - Schaffer, Andras
AU - Kim, Brian
AU - Dentchev, Tzvete
AU - Nagata, Satoshi
AU - Ise, Tomoko
AU - Showe, Louise C.
AU - Rook, Alain H.
N1 - Funding Information:
We are grateful to Xuming Mao for his suggestions and valuable discussions. This work was supported by NCI grant R01CA122569 and the Translation Research Grant from the Leukemia and Lymphoma Society (to AHR); and NCI grants RO1 CA 132098 (to LCS). The Wistar Institute Genomic and Bioinformatics facilities were supported by Cancer Center Support grant P30 CA010815. SN and TI were recipients of a NIH COBRE grant (1P20RR024219-01A2).
PY - 2014/1
Y1 - 2014/1
N2 - Sézary syndrome (SS) cells express cell surface molecules also found on normal activated CD4 T cells. In an effort to find a more specific surface marker for malignant SS cells, a microarray analysis of gene expression was performed. Results showed significantly increased levels of mRNA for CD164, a sialomucin found on human CD34+ hematopoietic stem cells, and FCRL3, a molecule present on a subset of human natural T regulatory cells. Both markers were increased in CD4 T cells from SS patients compared with healthy donors (HD). Flow cytometry studies confirmed the increased expression of CD164 and FCRL3 primarily on CD4+CD26- T cells of SS patients. Importantly, a statistically significant correlation was found between an elevated percentage of CD4+CD164+ T cells and an elevated percentage of CD4+CD26- T cells in all tested SS patients but not in patients with mycosis fungoides and atopic dermatitis or HD. FCRL3 expression was significantly increased only in patients with high tumor burden. CD4+CD164+ cells displayed cerebriform morphology and their loss correlated with clinical improvement in treated patients. Our results suggest that CD164 can serve as a marker for diagnosis and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expression correlates with a high circulating tumor burden.
AB - Sézary syndrome (SS) cells express cell surface molecules also found on normal activated CD4 T cells. In an effort to find a more specific surface marker for malignant SS cells, a microarray analysis of gene expression was performed. Results showed significantly increased levels of mRNA for CD164, a sialomucin found on human CD34+ hematopoietic stem cells, and FCRL3, a molecule present on a subset of human natural T regulatory cells. Both markers were increased in CD4 T cells from SS patients compared with healthy donors (HD). Flow cytometry studies confirmed the increased expression of CD164 and FCRL3 primarily on CD4+CD26- T cells of SS patients. Importantly, a statistically significant correlation was found between an elevated percentage of CD4+CD164+ T cells and an elevated percentage of CD4+CD26- T cells in all tested SS patients but not in patients with mycosis fungoides and atopic dermatitis or HD. FCRL3 expression was significantly increased only in patients with high tumor burden. CD4+CD164+ cells displayed cerebriform morphology and their loss correlated with clinical improvement in treated patients. Our results suggest that CD164 can serve as a marker for diagnosis and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expression correlates with a high circulating tumor burden.
UR - http://www.scopus.com/inward/record.url?scp=84890981726&partnerID=8YFLogxK
U2 - 10.1038/jid.2013.279
DO - 10.1038/jid.2013.279
M3 - Article
C2 - 23792457
AN - SCOPUS:84890981726
VL - 134
SP - 229
EP - 236
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
SN - 0022-202X
IS - 1
ER -